Moleculin
Manufacturing · Texas, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
5300 Memorial Dr Ste 950, Houston, Texas...Phone Number
(713) 300-5160Website
www.moleculin.comRevenue
<$5 MillionStock Symbol
MBRXIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Moleculin
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of highly resistant tumors and viruses. The Companys lead program, Annamycin, is intended to be a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.Explore more
Moleculin Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Moleculin your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Moleculin has recently received funding, and reach out quickly before it becomes old news!
Check out if Moleculin is spiking on competitors!
Earning: See what the market has to say on Moleculin recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Moleculin
Funding: Get notified immidiatlly once Moleculin has new funding data
Product Launch: Get notified when Moleculin launches new products
Website visits: Recent activity has been detected on your website
Moleculin, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Moleculin had a recent Job posting/layoffs
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Moleculin
Compare insights from companies similar to Moleculin, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Moleculin is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Moleculin is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Moleculin.
Moleculin financials insights
Gather financial insights about Moleculin, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Debt
$1.4M
2016
Stock Offering
$9.2M
Moleculin Tech Stack
A closer look at the technologies used by Moleculin
See more technologies
Most Recent Scoops
Earnings
Earnings, Finance
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Person-Based
Person-Based
Moleculin News & Media
Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than Control
HOUSTON, June 30, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced positive preliminary unblinded efficacy results from the first 45 patients enrolled in Part A of the Company's pivotal Phase 2/3 MIRACLE trial, analyzed on a full intent-to-treat basis with no patient exclusions. Both Annamycin treatment arms demonstrated favorable efficacy trends compared with the control arm in patients with relapsed or refractory acute myeloid leuIndependent Market Research Finds Strong Physician Intent to Prescribe Moleculin's Annamycin in Relapsed/Refractory AML
Surveyed oncologists reported high likelihood to prescribe (6 of 7), citing deep remissions, transplant-bridging potential, biomarker-agnostic use and reduced cardiotoxicity as key driversMoleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline Limits
Independent Cleveland Clinic Cardiac Review Supports Potential Best-in-Class Safety Profile as MIRACLE Phase 2b/3 Trial Advances
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Moleculin
Sign Up For FreeTo access detailed company insights
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of highly resistant tumors and viruses. The Companys lead program, Annamycin, is intended to be a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no ca... Read More
